CFTR and cystic fibrosis: To achieve site-specific editing of CFTR, poly (lactic-co-glycolic) acid (PLGA) nanoparticles have been used to deliver peptide nucleic acids (PNAs) to correct F508del CFTR mutation in vitro in human bronchial epithelial cells and in vivo in a CF murine model (McNeer et al., 2015).